Medicated Lenses

Contact Us

*

*

* Required

Leo Lens uses its proprietary technology to develop contact lenses that provide sustained drug delivery of medications for ocular disease using the power of digital printing on existing FDA-approved contact lenses.

This  method for treating glaucoma, other eye disease and allergies offers non-invasive, cost effective treatment through improved bioavailability, better patient compliance and reduced side effects. Our innovative solutions for using cutting edge technology, mitigates regulatory risks,  works seamlessly with existing manufacturing processes and offers doctors the flexibility of prescribing more than one drug for delivery. The value added benefits across supply chain of manufacturer, doctor and patients would make it a first choice treatment.

The ProblemThe Leo Lens Solution

Current glaucoma treatment methods are ineffective or invasive and expensive

  • 90% of drug delivery by eye drops

    • Eye drops are simple to apply but:
      • Low bioavailability
      • Poor compliance
      • Side effects
  • 10% use implants, inserts, or plugs

    • Effective but invasive and expensive
    • Not easy to remove or change perscription

Global Glaucoma Market = 70 Million Patients
$6B /Annum
Over 50 years of research and still no commercial solution for treatment via contact lenses.

Novel Approach + Enabling Technology = Commercial Product

Use FDA Approved MaterialsLeverage Existing Lens ManufacturingApply Digital PrintingTherapeutic Lens with Sustained Drug Delivery

Product Pipeline

Glaucoma

Lenses showed sustained release of more than 7 days during in vivo studies.

Concept level clinical evaluation with patients is the next step.

Dry Eye

In-vivo sustained release for 7 days

Allergy

In-vitro sustained release for 10 days

Multiple Drugs

Allergy & Comfort Enhancement

In-vitro sustained release from the same lens for 7 days

Value Added BenefitsCompetitive Advantages

Value Added Benefits Across the Supply Chain

Patients

Low cost/simple to use

Higher bioavailability

Better compliance

Reduced side effects

Comprehensive solution

Non-invasive

Clinicians

Low risk, non-invasive treatment

Better patient outcome

Predictable treatment plan

Fewer complications due to reduced side effects

Customized prescription

Reduced cost of medical treatment / Reduced hospitalization

Manufacturers

Low cost / high-quality products

Low capital investment

Reduced regulatory complexities

Patent protection

First in the market

Pipeline for multiple products

Patients Clinicians Manufacturers
Low cost / simple to use Low risk, non-invasive treatment Low cost / high quality products
Higher bioavailability Better patient outcome Low capital investment
Better compliance Predictable treatment plan Reduced regulatory complexities
Reduced side effects Fewer complications due to reduced side effects Patent protection
Comprehensive solution Customized prescription First in the market
Non-invasive Reduced cost for medical treatment / Reduced hospitalization Pipeline for multiple products

Competitive Advantages

Factor Rationale Eye Drops Injection/ Implants LTT Contact Lens
High Bioavailability Sustained delivery. Avoid fluctuations in IOP
Low Risk of Side Effects Avoids giving patient dry eye, infection
High Level of Patient Compliance Better patient outcomes from improved compliance
Low-Cost Manufacturers require acceptable gross margins to participate in this space
Easy to Insert and Remove Non-invasive treatment safe and low-cost Change in medical conditions, requires change in treatment
Delivers Multiple Drugs Customized treatment for patients. Provide lens comfort and treat multiple diseases simultaneously

Contact Us

*

*

* Required